Dupilumab for the treatment of atopic dermatitis: A clinical trial review.

Expert Opin Biol Ther

a 1 Wake Forest School of Medicine, Center for Dermatology Research, Medical Center Boulevard, Department of Dermatology , Winston-Salem, NC, USA +1 33 67 16 77 40 ; +1 33 67 16 77 32 ;

Published: June 2016

Introduction: Current treatment options for moderate-to-severe atopic dermatitis (AD) are limited and have potentially dangerous side effects. Dupilumab is a novel monoclonal antibody that was recently studied in adult patients with moderate-to-severe AD. Dupilumab inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in asthma. Considering that both AD and asthma are Th2 cell-mediated inflammatory processes, it is reasonable to suspect that dupilumab would be beneficial in AD.`

Areas Covered: This article is a review of the one major clinical trial that assessed the efficacy of dupilumab in patients with AD. Its goal is to provide a comparison to the current modalities for the treatment of AD and expert insight regarding future studies.

Expert Opinion: The results of this study are a significant therapeutic advancement. Dupilumab was shown to provide a mean percent change in Eczema Area and Severity Index score of -74% ± 3.6, in addition to, statistically and clinically significant reductions the severity, symptomatology, and morbidity associated with AD. However, the small sample size makes it difficult to assess the magnitude of this effect. As a result, dupilumab will likely be reserved for cases of severe AD unresponsive to traditional modalities.

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2015.1076388DOI Listing

Publication Analysis

Top Keywords

atopic dermatitis
8
clinical trial
8
dupilumab
7
dupilumab treatment
4
treatment atopic
4
dermatitis clinical
4
trial review
4
review introduction
4
introduction current
4
current treatment
4

Similar Publications

A niche in the context of microorganisms defines the specific ecological role or habitat inhabited by microbial species within an ecosystem. For the human commensal Malassezia, the skin surface is considered its primary niche, where it adapts to the skin environment by utilising lipids as its main carbon and energy source. However pathogenic characteristics of Malassezia include the production of allergens, immune modulation and excessive lipid utilisation, which result in several diseases such as pityriasis versicolor, seborrheic dermatitis, Malassezia folliculitis and atopic dermatitis.

View Article and Find Full Text PDF

Atopic dermatitis (AD) is a disease that significantly impacts the quality of life of patients. Although there are multiple evidence-based guidelines, they are usually aimed at providing recommendations to AD specialists rather than primary care physicians (PCPs). The aim of this study was to construct a consensus document for PCPs, with the aim of presenting evidence-based recommendations that allow general practitioners, family physicians, pediatricians, internists and emergency physicians to provide appropriate care to AD patients, facilitating their diagnosis, management, and avoiding delays that can deteriorate patients' f quality of life.

View Article and Find Full Text PDF

Background: An increasing body of evidence has suggested that the pathogenesis of Alzheimer's disease (AD) is not confined to the neurons but instead that neuroinflammation plays a significant role in the disease, with an interplay between the brain and the immune system. So far, their shared genetic components have not been systematically studied.

Method: We investigated the shared genetic architecture between AD and a plethora of immune-mediated diseases using the genome-wide association studies (GWAS) summary statistics data: allergic rhinitis, asthma, atopic dermatitis, celiac disease, Crohn's disease, hypothyroidism, primary sclerosing cholangitis, RA, systemic lupus erythematosus, ulcerative colitis, and vitiligo.

View Article and Find Full Text PDF

Addictions seem to be more frequent in atopic dermatitis and psoriasis patients than in the general population. This cross-sectional observational study comparatively evaluated substance-related and behavioural addictions in atopic dermatitis and psoriasis patients and analysed possible addiction patterns. From October 2023 to April 2024, 100 atopic dermatitis and 104 psoriasis patients at a German university hospital completed an anonymous questionnaire, including sociodemographic and health-related parameters, along with validated assessment tools for common addictions (smoking, gambling, alcohol, drugs, food, and internet).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!